![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
This perspective is part of an annual series of papers discussing drugs dropped from development in the previous year. Specifically, this paper focuses on the 19 cardiovascular drugs discontinued in 2011 after reaching preclinical or Phase I – III clinical trials. Information for this perspective is mainly derived from a search of Pharmaprojects.
Acknowledgement
H-p Zhao and H-m Jiang contributed equally to this work.
Notes
This box summarizes key points contained in the article.